Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fentanyl hydrochloride
Drug ID BADD_D00881
Description Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia.[A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin.[A179542] In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths).[L6748] Opioid overdoses kill an average of 11 Canadians daily.[L6751] Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]
Indications and Usage For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
Marketing Status Prescription; Discontinued
ATC Code N01AH01; N02AB03
DrugBank ID DB00813
KEGG ID D10811
MeSH ID D005283
PubChem ID 83932
TTD Drug ID D0E1WI
NDC Product Code 0406-1165
Synonyms Fentanyl | Phentanyl | Fentanest | Fentanyl Citrate | R-4263 | R 4263 | R4263 | Sublimaze | Transmucosal Oral Fentanyl Citrate | Duragesic | Durogesic | Fentora
Chemical Information
Molecular Formula C22H29ClN2O
CAS Registry Number 1443-54-5
SMILES CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Drug tolerance increasedMu-type opioid receptorP35372T47768Not Available
Drug tolerance increasedAdenylate cyclase type 1Q08828T63609Not Available
PainAbscisic acid-inducible protein kinaseQ02066Not AvailableNot Available
PainOpioid growth factor receptorQ9NZT2T13741Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Abscess11.01.08.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaemia01.03.02.001--
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site oedema12.07.01.020; 08.02.01.020--Not Available
Application site pain12.07.01.004; 08.02.01.004--Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Atelectasis22.01.02.001--
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Bradycardia02.03.02.002--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.003--Not Available
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Dehydration14.05.05.001--
Dermatitis bullous23.03.01.002--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages